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Background: Infectious agents have been shown to contribute to the development of lymphoid malignancies. The
different distribution of lymphoid malignancies in Asian and Western populations suggests possibly different
etiologies in Asian populations. Herpes zoster infection, commonly seen in immunocompromised persons, has been
reported to be associated with lymphoid malignancies in retrospective case–control studies from Western
populations, but the results are controversial and large-scale prospective studies from Asian populations are lacking.
Methods: A nationwide population-based matched-controlled prospective study on Taiwanese patients was
performed using the National Health Insurance Research Database from 1996 to 2007. Herpes zoster and
malignancies were defined by compatible ICD-9-CM (International Classification of Disease, 9th Revision, Clinical
Modification) codes. Patients who had been diagnosed with any malignancies before herpes zoster, with known
viral infections including human immunodeficiency virus, and duration from herpes zoster to diagnosis of
malignancies less than 6 months were excluded.
Results: Of 42,498 patients with herpes zoster prior to the diagnosis of any malignancies, the cumulative incidence
for lymphoid malignancies was 0.11% (n = 48), compared with 0.06% (n = 106) in 169,983 age- and
gender-matched controls (univariate hazard ratio (HR): 1.82, 95%CI: 1.29-2.55). The most common lymphoid
malignancy was non-Hodgkin’s lymphoma (60.4%, n = 29), followed by multiple myeloma (27.1%, n = 13). Risk for
developing lymphoid malignancies is significantly higher in herpes zoster patients (log rank P = 0.005). After
adjusting for presence of any comorbidities in Charlson comorbidity index, time-dependent covariate for herpes
group, and income category using Cox proportional hazard regressions, herpes zoster patients had an increased risk
of developing lymphoid malignancies (adjusted HR: 1.68, 95%CI: 1.35-2.42, P = 0.0026), but did not have an
increased risk of developing non-lymphoid malignancies (adjusted HR: 1.00, 95%CI: 0.91-1.05, P = 0.872).
Conclusion: Preceding herpes zoster infection is an independent risk marker for subsequent lymphoid
malignancies in Taiwanese subjects. Further studies are warranted for pathogenesis exploration and preventive
strategies in Asian populations.
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Lymphoid malignancies are characterized by the malig-
nant transformation of lymphoid cells and comprise a
group of heterogeneous diseases with distinctive clinical,
immunophenotypic and genetic features. The etiologies
remain poorly understood, but diseases that impair cel-
lular immunity such as human immunodeficiency virus
(HIV) infection and other immunodeficient diseases sig-
nificantly predispose to lymphoid malignancies [1-4].
Some host factors, including inherited genetic factors,
infections, autoimmune diseases, and environmental or
medication exposure have been found to be associated
with the development of lymphoid malignancies [4].
Recognition of the role of host infections in lymphoma-
genesis is important for prevention and management
strategies. Some viral infections have been found to be
associated with the development of certain lymphoid
malignancies, such as Epstein-Barr virus (EBV) and Bur-
kitt’s lymphoma, extranodal NK/T cell lymphoma,
human T-cell leukemia virus type 1 (HTLV-1) and adult
T cell leukemia/lymphoma, human herpes virus-8
(HHV-8) and primary effusion lymphoma, and hepatitis
C virus (HCV) and some B cell lymphomas [4-7]. How-
ever, the association between herpes zoster and subse-
quent lymphoid malignancies is still unclear.
Herpes zoster is typically characterized by unilateral
crops of painful and pruritic vesicles in a dermatomal
distribution, and is caused by reactivation of latent
varicella-zoster virus (VZV). The VZV establishes la-
tency in the dorsal root ganglia and its reactivation is
associated with a decline in cell-mediated immunity
[8,9]. The decline of VZV-specific cell-mediated immun-
ity may be either a natural consequence of aging or as a
result of immunosuppression [10]. Since impairment of
immunity is often linked with carcinogenesis, there have
been studies exploring the preceding herpes zoster infec-
tion as an indicator of subsequent cancer. Although
most of these studies indicated no obvious increase risk
of subsequent cancer [11,12], an increased risk of deve-
loping lymphoid malignancies was found from several
population-based case–control studies in patients with
history of herpes zoster infection, including chronic
lymphocytic leukemia (CLL) [13,14], multiple myeloma
or monoclonal gammopathy of undetermined signifi-
cance [15,16], and lymphoplasmacytic lymphoma or
Waldenstrom macroglobulinemia [17].
The distribution of lymphoid malignancies in Asia is
different from that in Western countries [18-22], indica-
ting racial and geographic differences in the etiologies of
lymphoid malignancies. Recognition of preceding factors
prior to lymphoid malignancies, especially infectious
agents, is important to understand the pathogenesis and
the distribution differences. However, little is known about
the association between herpes zoster and subsequent riskof lymphoid malignancies in Asian populations, as most
case–control studies are retrospective design from West-
ern populations and large-scale prospective studies from
Asian populations are lacking. Therefore, we performed a
matched-control prospective follow-up study from a na-
tionwide population-based dataset in Taiwan and tried to
explore the association between herpes zoster exposure
and the subsequent risk of lymphoid malignancies.
Methods
Data source
This study used the National Health Insurance Research
Database (NHIRD) from 1996 to 2007, which is derived
from the Taiwan National Health Insurance (NHI) pro-
gram and provides a sample of 1,000,000 random sub-
jects to scientists in Taiwan for research purposes. The
NHI program has been implemented in Taiwan since
1995, offering a comprehensive, unified, and universal
health insurance program to all citizens who have estab-
lished a registered domicile for at least four months in
the Taiwan area. The coverage rate was 96% of the whole
population in 2000 rising to 98.4% (22.6 million of the
country’s 22.96 million people) at the end of 2007. The
coverage provides outpatient services, inpatient care,
Chinese medicine, dental care, childbirth, physical the-
rapy, preventive health care, home care, and rehabilita-
tion for chronic mental illnesses. The NHI medical
claims database includes ambulatory care, hospital in-
patient care, dental services, and prescription drugs.
Therefore, the NHIRD is the largest and most complete
nationwide population-based dataset in Taiwan, and
there are no statistically significant differences in age,
sex, and average insured payroll-related amount between
the sample group and all enrollees. These features make
the dataset a valuable resource for examining the risk of
developing lymphoid malignancies among patients with
herpes zoster. Because the NHIRD database provided by
the official NHI program consists of totally de-identified,
encrypted, secondary data released to the public for re-
search purposes without personal or institutional identi-
fication or contact with the study patients, the study was
exempt from full review by the institutional review
board (IRB) of Kaohsiung Medical University. The study
also conformed to the criteria of exemption of IRB re-
view and exemption of obtaining informed consents
which were announced by the Department of Health.
Study sample
We selected all patients who had visited ambulatory care
centers for the treatment of herpes zoster between 1996
and 2007. Only patients who had the first herpes zoster
exposure were selected. We defined herpes zoster by
compatible ICD-9-CM (International Classification of
Disease, 9th Revision, Clinical Modification) codes of
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for inpatient or outpatient care. The definition of lym-
phoid malignancies was derived from the 2008 WHO
classification of tumours of hematopoietic and lymphoid
tissues [1], and cases were identified by compatible ICD-
9-CM codes including Hodgkin’s disease (code 201.0-
201.9), non-Hodgkin’s lymphoma (code 200.0-200.8,
202.0-202.9), multiple myeloma (code 203.0-203.1), and
lymphoid leukemia (code 204.0-204.9). We excluded
patients who had been diagnosed with any lymphoid
malignancies or any cancers (code 140.0-199.1) before
herpes zoster. Furthermore, we excluded patients who
had been diagnosed with other viral infections (code
045.0-052.9, 054.0-066.9, 070–079.9) and HIV infection
(code 042) before the diagnosis of lymphoid malignan-
cies. Patients with their duration from herpes zoster to
diagnosis of any malignancies less than 6 months were
also excluded. In total, 42,498 patients with herpes zos-
ter were included in the study group. The first ambula-
tory care visit for the treatment of herpes zoster was
assigned as the index visit.
The matched-control group was likewise extracted
from the Registry of Beneficiaries of the NHIRD. We
randomly selected 169,983 control subjects (4 for every
herpes zoster patient), matched with the study group in
terms of age, sex, and the year and month of index visit.
After matching with age and sex, the month of index
visit of the matched cases was assigned the same as the
index visit of study group, and follow-up started 6
months after the index visit. Similar to the study group,
patients who had lymphoid malignancies or any cancers
before their index ambulatory care visit, who had other
viral infections (code 045.0-052.9, 054.0-066.9, 070–
079.9) and HIV infection (code 042) before the diagnosis
of lymphoid malignancies, and patients with an interval
from index visit to the diagnosis of any malignancies of
less than 6 months were excluded in the control group.
Statistical analysis
The chi-square test was used to compare the distribution
of demographic characteristics between patients with and
without herpes zoster. Time-to-event analysis involved es-
timating the probability that lymphoid malignancies
would occur at different points in time. The end-point of
follow-up in those who developed lymphoid malignancies
was the date of diagnosis, and in those who did not de-
velop lymphoid malignancies was the end of observation
(December 31, 2007), to arrive at “censored” data.
Kaplan-Meier estimates were computed to compare the
difference in developing lymphoid malignancies between
patients with and without herpes zoster.
The univariate and multivariate proportional hazards
model was applied to estimate the risk effect on develop-
ing lymphoid malignancies and all malignancies(excluded lymphoid malignancies). The assessment of
comorbidities was performed in the year before the
index visit and was integrated into multivariate analysis
model. One of the most commonly used comorbidities
index to rate the impact on index disease in various
medical researches is Charlson comorbidity index (CCI)
[23-25]. The CCI was developed by assigning weights for
19 chronic conditions, taking into account of the num-
ber and seriousness of comorbid diseases. The cova-
riates in the analysis model included age, sex, income
category (monthly income ≦USD 800; monthly income
>USD 800), time-dependent covariate for herpes zoster
group, and existence of any chronic conditions listed in
the CCI. To exclude the possibility that the adjusted
hazard ratio (HR) of herpes zoster is influenced by any
comorbidities, each adjusted HR for herpes zoster was
calculated from different models by adjusting all comor-
bidities, and by adjusting comorbidities with step-wise
removal of one comorbidity at one time. All statistics
were calculated using SAS 9.2 software. All P values are
two-sided.
Results
The demographic characteristics and comorbid medical
disorders of the patients with herpes zoster and the con-
trol group matched in terms of age, sex and the year and
month of index visit are shown in Table 1. The comor-
bidities were derived from the items listed in the CCI. A
total of 42,498 patients were found to have herpes zoster
prior to the diagnosis of any malignancies. The mean
age was 48.92 years (± 20.67 years), with a mild female
predominance (52.4%). The demographic characteristics
between the patients and controls were largely different
in distribution. In general, herpes zoster patients had
more comorbidities than controls, except for myocardial
infarction, dementia, hemiplegia or paraplegia, and mo-
derate or severe liver disease (Table 1).
The proportion of those developing lymphoid malig-
nancies or any cancers (excluding lymphoid malignan-
cies) of the patients and controls is shown in Table 2.
Among the patients with herpes zoster, 2.42% (n =
1,027) subsequently developed cancer, and 0.11% (n = 48)
lymphoid malignancy. Among the controls, 2.26% (n =
3,838) of the patients subsequently developed cancer, and
0.06% (n = 106) lymphoid malignancy. Among 48 herpes
zoster infected patients who developed subsequent lym-
phoid malignancies, the most common lymphoid malig-
nancy was non-Hodgkin’s lymphoma (60.4%, n = 29),
followed by multiple myeloma (27.1%, n = 13). Patients
with herpes zoster had a significantly increased risk of
developing any cancers (excluding lymphoid malignancies,
univariate HR: 1.07, 95% CI: 1.01-1.15), and lymphoid ma-
lignancies (univariate HR: 1.82, 95% CI: 1.29-2.55) com-
pared with the control group. The Kaplan-Meier estimates






Odds ratio 95% CI P value
Total 42,498 169,983
Follow-up - - -
Total person-years 168,992 684,001
Average person-years 3.976 4.024
Sex - - 0.9874
Female 52.4 52.4
Male 47.6 47.6
Age, years-old - - 1.0000




< 30 16.6 16.6
Comorbidities (%)
Myocardial infarct 1.4 1.2 1.12 0.95-1.33 0.1846
Congestive heart failure 4.6 3.7 1.28 1.18-1.39 <0.0001
Peripheral vascular disease 2.0 1.6 1.32 1.15-1.51 <0.0001
Cerebrovascular disease 10.5 9.5 1.19 1.13-1.25 <0.0001
Dementia 1.3 1.4 1.12 0.99-1.27 0.0667
Chronic pulmonary disease 29.6 24.6 1.38 1.33-1.43 <0.0001
Rheumatologic disease 4.2 2.9 1.92 1.74-2.10 <0.0001
Peptic ulcer disease 25.7 21.2 1.40 1.35-1.45 <0.0001
Mild liver disease 18.0 15.0 1.33 1.27-1.39 <0.0001
Diabetes (mild to moderate) 13.3 11.1 1.33 1.28-1.39 <0.0001
Diabetes (with chronic complications) 4.0 3.2 1.36 1.26-1.47 <0.0001
Hemiplegia or paraplegia 1.0 1.1 1.13 0.94-1.36 0.1897
Renal disease 6.0 4.8 1.43 1.33-1.54 <0.0001
Moderate or severe liver disease 0.4 0.4 1.09 0.82-1.45 0.9568






Presence of lymphoid malignancy
Yes, no. (%) of patients 154 (0.07) 48 (0.11) 106 (0.06)
No, no. (%) of patients 212,105 (99.93) 42,348 (99.89) 169,757 (99.94)
Univariate HRa (95% CI) - 1.82 (1.29-2.55) Reference
P value 0.0006
Presence of cancer (excluded lymphoid malignancy)
Yes, no. (%) of patients 4,865 (2.29) 1,027 (2.42) 3,838 (2.26)
No, no. (%) of patients 207,590 (97.71) 41,458 (97.58) 166,132 (97.74)
Univariate HRa (95% CI) - 1.07 (1.01-1.15) Reference
P value 0.0465
aHR: Hazard ratio.
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among the patients with herpes zoster and the controls
are shown in Figure 1. Risk for developing lymphoid
malignancies is significantly higher in herpes zoster
patients than in the matched-controlled cohort (log
rank p = 0.005).
To adjust for potentially confounding factors and sur-
vival bias, covariates of CCI, income category, and
time-dependent covariate for herpes zoster group were
added to Cox proportional hazard regressions. After
adjusting for existence of any comorbidities listed in
the CCI and income category, patients with herpes zos-
ter had an increased risk of developing lymphoid malig-
nancies (adjusted HR: 1.68, 95% CI: 1.35-2.42, P =
0.0026), but did not have an increased risk of develop-
ing non-lymphoid malignancies (adjusted HR: 1.00,
95% CI: 0.91-1.05, P = 0.872) (Table 3). To exclude the
possibility that the adjusted HR is influenced by any
comorbidities, each adjusted HR for herpes zoster was
calculated from different models by adjusting all
comorbidities and by adjusting comorbidities with
step-wise removal of one comorbidity at one time. The
adjusted HR for herpes zoster showed similar value
from different models (1.67-1.76, Additional file 1:
Table S1), indicating that the influence of any comor-
bidities on the adjusted HR is low, and herpes zoster is
an independent risk marker for subsequent lymphoid
malignancies.Figure 1 The cumulative incidence of lymphoid malignancies among
Kaplan-Meier estimates of the cumulative incidence of lymphoid malignan
significantly higher in herpes zoster patients than in the matched-controlleDiscussion
This study is a large population-based matched-control
prospective follow-up survey on a Taiwanese population
to explore the association between herpes zoster and the
subsequent risk of lymphoid malignancies. To the best
of our knowledge, this is currently the largest matched-
control study of an Asian population. Our results
showed that preceding herpes zoster infection is an
independent risk marker for subsequent lymphoid ma-
lignancies in Taiwanese subjects from univariate and
multivariate analyses. There are several retrospective
case–control studies that have explored the risks of pre-
ceding infections and subsequent lymphoid malignancies
in Western populations [13-17]. Among the preceding
infections, herpes zoster was shown to be associated with
both Hodgkin’s disease and non-Hodgkin’s lymphoma in
a hospital-based case–control study in Italy [26] and an
increased risk of CLL in male U.S. veterans [13]. In a
large case–control study using the U.S. SEER database,
herpes zoster showed an increased risk of CLL and the
risk increased with increasing severity or frequency of
herpes zoster [14]. An increased risk of multiple myeloma
or monoclonal gammopathy of undetermined significance
was found in patients with history of herpes zoster in Italian
and in white and black male U.S. veterans [15,16]. Simi-
larly an increased risk of lymphoplasmacytic lymphoma
or Waldenstrom macroglobulinemia was found from
Swedish population-based registries [17].patients with herpes zoster and matched-controlled cohort. The
cies showed the risk for developing lymphoid malignancies is
d cohort (log rank p = 0.005).
Table 3 Adjusted hazard ratios for lymphoid malignancy and all malignancies (excluding lymphoid malignancy)
Variable Adjusted HRa for
lymphoid malignancy
(95% CI)






Yes 1.68 (1.35-2.42) 0.0026 1.00 (0.91-1.05) 0.872
Charlson comorbidity indexb
No Reference Reference
Yes 2.33 (1.66-3.27) <0.0001 2.92 (2.75-3.11) <0.0001
Income category (monthly)
≤ USD 800 Reference Reference
> USD 800 0.58 (0.36-0.93) 0.023 0.63 (0.58-0.68) <0.0001
aHR: Hazard ratio. Adjusted by Charlson comorbidity index, time-dependent covariate for herpes zoster group, and income category.
bPresence of any comorbidities listed in Charlson comorbidity index.
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of internal malignancies has been reviewed for decades,
however most studies have not found an association be-
tween herpes zoster and an increased risk for the deve-
lopment of future malignancies [11,12]. In our study, the
association of herpes zoster and risk of cancer was seen
in lymphoid malignancies but not in non-lymphoid ma-
lignancies, which is compatible with other studies and
suggests that herpes zoster is an independent risk mar-
ker for lymphoid malignancies but not a risk marker for
other cancers.
Some host factors have been found to be associated
with the development of lymphoma including inherited
genetic factors, infections, autoimmune diseases, and en-
vironmental exposure [4]. HIV-AIDS is a known risk
factor for lymphoid malignancies [1-4], and patients with
HIV infection and other known viral infections that
could be coded from the ICD-9-CM were excluded in
our analysis to exclude the influence of viruses other
than herpes zoster. Autoimmune diseases and chronic
inflammatory disorders have been shown to be asso-
ciated with lymphoid malignancies [27-29]. Although
the proportion of autoimmune diseases in patients was
higher than in the controls (4.2% vs. 2.9%), the cova-
riates of CCI including rheumatologic diseases were
adjusted in Cox proportional hazard regressions, and a
relatively small difference was noted in adjusted HRs
from step-wise removal of comorbidities, indicating that
the influence of autoimmune diseases is low. Similarly,
other systemic comorbidities may play a role in the asso-
ciation with the development of lymphoid malignancies.
The adjustment of covariates of CCI, and a relatively
small difference in adjusted HRs from step-wise removal
of comorbidities, are helpful to diminish the confound-
ing factors caused by systemic comorbidities.
The total case number of herpes zoster (n = 42,498) in
our cohort before diagnosis of any malignancies iscomparable with some studies focusing on herpes zoster
using Taiwan NHIRD [30,31], which showed the inci-
dence rate of herpes zoster in Taiwan is estimated
around 4.89 to 4.97 cases per 1000 person-years, indica-
ting the possibility of underdetection in our cohort is
low. In addition, our dataset contained inpatient and
outpatient compartments, preventing the selection and
information bias common in hospital-based studies.
Moreover, most of the published study designs have
been retrospective case–control studies. Prospective
study that shows infection preceded lymphoid malignan-
cies and that infection is associated with subsequently
elevated lymphoid malignancies risk can be especially
compelling.
The distribution of lymphoid malignancies in Asian
populations is different from those in Western countries
[18-22]. The incidence of low grade lymphoma, CLL,
and Hodgkin’s disease is lower than in Western popula-
tions, and the incidence of T cell lymphoma is higher, in-
dicating racial or geographical differences in the etiology
of lymphomagenesis. Although the cause is unclear,
searching for an antecedent exposure history prior to
lymphoid malignancies is helpful in determining the
causes of the geographical differences. Furthermore, to
better clarify the role of antecedent herpes zoster infec-
tion with subsequent lymphoid malignancies, it is im-
portant to perform analysis in a different population.
Our study provides evidence supporting the association
between herpes zoster infection and the subsequent de-
velopment of lymphoid malignancies in Taiwanese sub-
jects, and warrants further studies to explore the
mechanism between herpes zoster and lymphomagenesis.
Many studies have attempted to explore the mecha-
nisms between viral infections and lymphomagenesis.
The potential mechanisms by which most viruses play a
role in lymphomagenesis are by introducing alternations
in the genome through the incorporation of viral genes,
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flammation [4]. Some viral infections, like EBV, can di-
rectly infect and transform lymphocytes, disrupt normal
cell function, and promote cell division [6]. The HIV in-
fection is uinque in causing depletion of CD4+ T-cells
and induces profound cell-mediated immunodeficiency
which permits dysregulated proliferation of B lympho-
cytes. Some viral infections, like HCV, may induce
chronic immune stimulation and persistent lymphocytes
activation [6]. Although the mechanism between VZV
and lymphomagenesis is currently unknown, the fact
that the VZV establishes latency after primary infection,
and herpes zoster results from a reactivation of latent
VZV infection which is often associated with a decline
in cell-mediated immunity [8,9] imply the possibility of
the role of chronic immune stimulation. At the same
time, since the decline of VZV-specific cell-mediated im-
munity may be a consequence of immunosuppression
[10], an alternative explanation is that the herpes zoster
infection is a marker of immune suppression, and such
an immune suppressed condition is a potential cause of
lymphoid malignancies thus herpes zoster infection is a
risk marker for subsequent lymphoid malignancies. Fur-
ther studies are needed to determine if VZV may trigger
continuous antigenic and immune stimulation, or a dis-
turbed immune function, and how these may be asso-
ciated with the development of lymphoid malignancies.
There are limitations to our study. First, the ICD-9-
CM coding system is not sufficient to classify the sub-
types of lymphoid malignancies according to the 2008
WHO classification and the limited events during
follow-up (n = 48), leading to difficulty in performing
histological subtype analysis, although most of cases
were non-Hodgkin’s lymphoma and multiple myeloma.
Second, although history of previous viral infections was
excluded, there were still viral infections whose compa-
tible ICD-9-CM code could not be found, including EBV
and HHV-8. However, since Taiwan is known an en-
demic area of EBV infection and most adults are EBV-
infected [32], and HHV-8 related primary effusion
lymphoma is very rare, it is likely that the influence of
un-coded viral infections in patients and control group
is similar. Third, the possibility of some herpes zoster in-
fection being missed or inaccurately diagnosed exists.
However, it is likely that the possibility did not differ be-
tween cases and controls, and herpes zoster has unique
clinical presentations. Forth, analyzing the combined
outcomes of all malignancies and lymphoid malignancies
in both groups may be a limitation because there are
many distinct entities with different etiologies of lymph-
oid malignancies. As such what we measured is an ave-
rage association between herpes zoster and all lymphoid
malignancies. Lastly, although several adjusted analyses
had been performed to exclude the influence of medicalcomorbidities listed in CCI, there may be unmeasured
confounding effects by other medical illness that have
not been captured. The possibility that a few HIV-
infected people being missed in the claims database is
low because HIV-infected patients before diagnosis of
any malignancies were excluded; HIV exam is an essen-
tial part when lymphoid malignancies are diagnosed; no
patients were found to have HIV infection during
follow-up; and HIV-infected patients have a mark in
their own insurance card and they will not get the insu-
rance coverage for HIV management if no HIV ICD-9-
CM code was claimed.Conclusion
Preceding herpes zoster infection is an independent risk
marker for subsequent lymphoid malignancies in Taiwanese
subjects from a large population-based matched-control
prospective follow-up survey. The role of VZV in lym-
phomagenesis and the possibility of chronic immune
stimulation or disturbed immune function warrant fur-
ther clarification. Further studies are also needed for
pathogenesis exploration and preventive strategies in
Asian populations.Additional file
Additional file 1: Table S1. The adjusted hazard ratio of herpes zoster
and the relationship with comorbidities.
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